ArticleHaematologica2020
Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
Abstract readLetter
In one paragraph
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis.Blood advances · 2024Pooled it
- Clinical management of clonal hematopoiesis.Cancer · 2026Review
- Is clonal haematopoiesis the missing link between lupus and cardiovascular disease?Rheumatology (Oxford, England) · 2026Review
- Review
- Target practice: Opportunities for therapeutic intervention in CHIP and CCUS.Blood reviews · 2025Review
- Joint involvement in VEXAS and non-VEXAS clonal haematopoiesis: two clusters from a multicentre regional cohort.RMD open · 2025Article
- Expert Perspective: Hematologic Malignancies and Vasculitis.Arthritis & rheumatology (Hoboken, N.J.) · 2025Review
- VEXAS syndrome.International journal of hematology · 2025Review
- Clonal Hematopoiesis of Indeterminate Potential in Crohn's Disease and Ulcerative Colitis.Inflammatory bowel diseases · 2025Article
- Clonal Hematopoiesis and Thrombosis.American journal of hematology · 2025Review
- Review
- Deciphering Clonal Hematopoiesis of Indeterminate Potential: Methods, Mechanisms, and Implications for Kidney Diseases.Journal of the American Society of Nephrology : JASN · 2025Review
- Clonal Hematopoiesis in Women With Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Review
- CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease.Blood advances · 2025Review
- Clones in blood and stratified epithelial cells, and their drivers.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2025Review
- Somatic mutations in autoinflammatory and autoimmune disease.Nature reviews. Rheumatology · 2024Review
- Clonal Hematopoiesis of Indeterminate Potential in Crohn's Disease and Ulcerative Colitis.medRxiv : the preprint server for health sciences · 2024Article
- Clonal expansion in normal tissues.Cancer science · 2024Review
- Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu's arteritis, ANCA-associated vasculitis and giant cell arteritis.Annals of the rheumatic diseases · 2024Article
- Clonal haematopoiesis, ageing and kidney disease.Nature reviews. Nephrology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Christopher Maximilian ArendsCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin.
Marlene WeissExperimental and Clinical Research Center, Charité, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin.
Friederike ChristenCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin.
Claudia Eulenberg-GustavusExperimental and Clinical Research Center, Charité, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin.
Anthony RousselleExperimental and Clinical Research Center, Charité, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin.
Ralph KettritzExperimental and Clinical Research Center, Charité, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin.
Kai-Uwe EckardtCharité - Universitätsmedizin Berlin, Department of Nephrology and Intensive Care Medicine, Berlin.
Willy ChanCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin.
Kaja HoyerCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin.
Mareike FrickCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin.
Lars BullingerCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin.
Markus BieringerHELIOS Klinikum Berlin-Buch, Department of Cardiology and Nephrology, Berlin, Germany.
Adrian SchreiberExperimental and Clinical Research Center, Charité, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin adrian.schreiber@charite.de.
Frederik DammCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin frederik.damm@charite.de.
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MNCATS NIH HHS UL1 TR001863
Abstract
PubMed holds no abstract for this paper.
Indexed as
Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisClonal HematopoiesisHumansPeroxidasePeroxidase
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.